دورية أكاديمية
أعرض في EDS

Decellularization of xenografted tumors provides cell-specific in vitro 3D environment.

التفاصيل البيبلوغرافية
العنوان: Decellularization of xenografted tumors provides cell-specific in vitro 3D environment.
المؤلفون: Iazzolino G; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Mendibil U; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain.; TECNALIA, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Arnaiz B; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Ruiz-de-Angulo A; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Azkargorta M; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain., Uribe KB; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Khatami N; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Elortza F; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain., Olalde B; TECNALIA, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Gomez-Vallejo V; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Llop J; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain., Abarrategi A; Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastian, Spain.; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
المصدر: Frontiers in oncology [Front Oncol] 2022 Aug 18; Vol. 12, pp. 956940. Date of Electronic Publication: 2022 Aug 18 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مستخلص: In vitro cell culture studies are common in the cancer research field, and reliable biomimetic 3D models are needed to ensure physiological relevance. In this manuscript, we hypothesized that decellularized xenograft tumors can serve as an optimal 3D substrate to generate a top-down approach for in vitro tumor modeling. Multiple tumor cell lines were xenografted and the formed solid tumors were recovered for their decellularization by several techniques and further characterization by histology and proteomics techniques. Selected decellularized tumor xenograft samples were seeded with the HCC1806 human triple-negative breast cancer (TNBC) basal-like subtype cell line, and cell behavior was compared among them and with other control 2D and 3D cell culture methods. A soft treatment using Freeze-EDTA-DNAse allows proper decellularization of xenografted tumor samples. Interestingly, proteomic data show that samples decellularized from TNBC basal-like subtype xenograft models had different extracellular matrix (ECM) compositions compared to the rest of the xenograft tumors tested. The in vitro recellularization of decellularized ECM (dECM) yields tumor-type-specific cell behavior in the TNBC context. Data show that dECM derived from xenograft tumors is a feasible substrate for reseeding purposes, thereby promoting tumor-type-specific cell behavior. These data serve as a proof-of-concept for further potential generation of patient-specific in vitro research models.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Iazzolino, Mendibil, Arnaiz, Ruiz-de-Angulo, Azkargorta, Uribe, Khatami, Elortza, Olalde, Gomez-Vallejo, Llop and Abarrategi.)
References: Biomaterials. 2017 Apr;124:211-224. (PMID: 28209528)
Biomed Eng Online. 2019 Jun 4;18(1):71. (PMID: 31164131)
Surg Today. 2020 Jul;50(7):633-643. (PMID: 32363425)
Cancers (Basel). 2022 Apr 26;14(9):. (PMID: 35565301)
Front Oncol. 2020 Mar 31;10:428. (PMID: 32296646)
Nat Methods. 2009 May;6(5):359-62. (PMID: 19377485)
J Cell Commun Signal. 2011 Aug;5(3):239-48. (PMID: 21499821)
Blood Cancer Discov. 2021 Mar;2(2):135-145. (PMID: 33778768)
J Cell Physiol. 2019 Jun;234(6):9447-9456. (PMID: 30478896)
Adv Drug Deliv Rev. 2014 Dec 15;79-80:40-9. (PMID: 24996134)
Sci Rep. 2021 Jun 25;11(1):13334. (PMID: 34172801)
Cancers (Basel). 2022 Feb 17;14(4):. (PMID: 35205760)
J Cell Physiol. 2021 Jun;236(6):4709-4724. (PMID: 33368325)
Biophys Rev. 2018 Dec;10(6):1695-1711. (PMID: 30406572)
J Clin Med. 2019 Dec 11;8(12):. (PMID: 31835761)
Nat Rev Mater. 2019 Sep;4(9):606-622. (PMID: 33552558)
J Cell Sci. 2012 Jul 1;125(Pt 13):3015-24. (PMID: 22797912)
Bioact Mater. 2021 Feb 15;6(9):2767-2782. (PMID: 33665508)
Cancers (Basel). 2021 Oct 06;13(19):. (PMID: 34638490)
Nat Med. 2010 Aug;16(8):927-33. (PMID: 20628374)
Front Bioeng Biotechnol. 2019 Sep 12;7:217. (PMID: 31572718)
Biofabrication. 2014 Jun;6(2):022001. (PMID: 24727833)
Materials (Basel). 2019 Apr 22;12(8):. (PMID: 31013621)
Front Oncol. 2020 Jul 23;10:1195. (PMID: 32793490)
Transl Res. 2022 Sep;247:117-136. (PMID: 34844003)
Nat Biotechnol. 2008 Dec;26(12):1367-72. (PMID: 19029910)
Int J Mol Sci. 2020 Jul 30;21(15):. (PMID: 32751654)
Trends Cancer. 2021 Mar;7(3):249-264. (PMID: 33218948)
Molecules. 2016 Oct 10;21(10):. (PMID: 27735867)
Sci Rep. 2015 Aug 07;5:13079. (PMID: 26248878)
Front Oncol. 2021 Oct 25;11:733652. (PMID: 34760696)
Ann Biomed Eng. 2020 Jul;48(7):2064-2077. (PMID: 31617045)
J Clin Invest. 2017 Feb 1;127(2):543-548. (PMID: 28067666)
Sci Rep. 2018 Mar 15;8(1):4608. (PMID: 29545552)
Cancers (Basel). 2021 Jun 13;13(12):. (PMID: 34199324)
Cancers (Basel). 2020 Sep 24;12(10):. (PMID: 32987868)
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70. (PMID: 25969447)
Theranostics. 2019 Apr 13;9(9):2439-2459. (PMID: 31131046)
Trends Biotechnol. 2020 Dec;38(12):1397-1414. (PMID: 32416940)
Oncotarget. 2015 Nov 24;6(37):39676-91. (PMID: 26485755)
Semin Cancer Biol. 2005 Oct;15(5):405-12. (PMID: 16055341)
Oncotarget. 2017 Apr 25;8(17):29487-29500. (PMID: 28412757)
J Tissue Eng. 2022 Apr 25;13:20417314221091682. (PMID: 35495097)
Cancers (Basel). 2022 Jan 12;14(2):. (PMID: 35053521)
Tissue Eng Part A. 2011 Nov;17(21-22):2583-92. (PMID: 21883047)
Exp Cell Res. 2010 Mar 10;316(5):813-25. (PMID: 20067788)
Toxicol Res. 2014 Mar;30(1):1-5. (PMID: 24795792)
Adv Drug Deliv Rev. 2014 Apr;69-70:29-41. (PMID: 24636868)
Mater Sci Eng C Mater Biol Appl. 2019 Nov;104:109942. (PMID: 31499951)
Int J Reprod Biomed. 2021 Apr 22;19(4):321-332. (PMID: 33997591)
Cancers (Basel). 2021 Nov 30;13(23):. (PMID: 34885142)
PLoS One. 2014 Jul 29;9(7):e103672. (PMID: 25072252)
Acta Biomater. 2021 Sep 15;132:37-51. (PMID: 33711526)
Nat Methods. 2016 Sep;13(9):731-40. (PMID: 27348712)
Biomaterials. 2021 Aug;275:120983. (PMID: 34186236)
Mol Ther. 2022 Feb 2;30(2):672-687. (PMID: 34274535)
Mol Carcinog. 2018 Nov;57(11):1599-1607. (PMID: 30074275)
J Clin Invest. 2011 Jul;121(7):2750-67. (PMID: 21633166)
Cell Tissue Bank. 2021 Dec;22(4):575-585. (PMID: 34581914)
PLoS One. 2021 Mar 5;16(3):e0243682. (PMID: 33667231)
Cancers (Basel). 2021 Nov 22;13(22):. (PMID: 34831010)
فهرسة مساهمة: Keywords: 3D model; breast cancer; decellularization; in vitro; tumor xenograft
تواريخ الأحداث: Date Created: 20220905 Latest Revision: 20230328
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9434107
DOI: 10.3389/fonc.2022.956940
PMID: 36059712
قاعدة البيانات: MEDLINE
الوصف
تدمد:2234-943X
DOI:10.3389/fonc.2022.956940